Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Prourokinase in Acute Pulmonary Embolism
NCT03108833Phase 2Completed
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of recombinant human prourokinase in pulmonary embolism (PE) (3 arms), sponsored by Tasly Biopharmaceuticals Co., Ltd. Primary endpoints: Qanadli CT Score at 48 hours, Average Pulmonary Artery Pressure at 30 days and 7 more. Started Jun 2017; status: completed.
02
Drugs
recombinant human prourokinase
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT03108833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108833.